Начало・Списък с акции・CytoSorbents Corp

CytoSorbents Corp

Затворен

СекторЗдравеопазване

0.36

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.35

Максимум

0.36

Ключови измерители
By Trading Economics
Приходи	-4.4M -9.5M
Продажби	769K 9.6M
EPS	-0.07
Марж на печалбата	-99.107
Служители	129
EBITDA	547K -3.3M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+108.33% upside

Дивиденти
By Acuity
Следващи печалби	12.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-383K 23M
Предишно отваряне	0.36
Предишно затваряне	0.36

Настроения в новините

By Acuity

50%

135 / 340 Класиране в Healthcare

CytoSorbents Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.08.2026 г., 22:01 ч. UTC

Cytosorbents Corp shares are higher in after-market trading, following notable activity after the market closed, despite no specific company news identified.

10.08.2026 г., 19:21 ч. UTC

News

Cytosorbents Corp shares are higher, driven by gains in the Health Care Equipment sector. The company reported Q2 revenue of $9.63 million, exceeding forecasts.

7.08.2026 г., 20:51 ч. UTC

Cytosorbents Corp shares declined in after-hours trading, continuing lower since Friday's close, with no specific news identified to explain the movement.

6.08.2026 г., 19:16 ч. UTC

Cytosorbents Corp shares are higher during Thursday's session, continuing a strong upward trend since Wednesday's close, with no specific news identified for the increase.

5.08.2026 г., 22:06 ч. UTC

Cytosorbents Corp shares are higher in after-market trading, reaching a high of 2.63% following an initial dip. The stock remains above its 20-day moving average.

4.08.2026 г., 21:01 ч. UTC

Cytosorbents Corp shares are higher in after-market trading amid positive market sentiment linked to U.S.-Iran negotiations and declining crude oil prices.

3.08.2026 г., 19:56 ч. UTC

Cytosorbents Corp shares are higher during Monday's session, tracking a broader market uptick despite being below the 20-day moving average.

31.07.2026 г., 20:06 ч. UTC

Cytosorbents Corp. shares are trading roughly flat amid no specific news. The broader market also closed near unchanged since Thursday.

29.07.2026 г., 20:08 ч. UTC

Cytosorbents Corp shares are lower today, following an early peak and trading below the 20-day moving average. No specific news was identified for the decline.

28.07.2026 г., 18:46 ч. UTC

Cytosorbents Corp is trading higher during Tuesday's session, recovering from an earlier dip. No specific news was identified to explain the movement.

27.07.2026 г., 18:41 ч. UTC

Cytosorbents Corp shares are lower today amid notable volatility, with no specific news identified to explain the decline during Monday's session.

24.07.2026 г., 19:06 ч. UTC

Cytosorbents Corp shares are lower, marking three consecutive daily declines amid a broader market pullback influenced by falling crude oil prices.

22.07.2026 г., 20:13 ч. UTC

Cytosorbents Corp shares are lower in after-market hours amid rising crude oil prices and escalating U.S.-Iran tensions. The stock remains below its 20-day moving average.

21.07.2026 г., 18:31 ч. UTC

Cytosorbents Corp shares are higher today, reflecting broader market optimism despite earlier fluctuations. Strong buying in technology stocks supports this upward movement.

20.07.2026 г., 19:16 ч. UTC

News

Cytosorbents plans to report second-quarter 2026 results on August 6. The company is also pursuing FDA and Health Canada approval for its DrugSorb®-ATR device.

Сравнение с други в отрасъла

Ценова промяна

CytoSorbents Corp Прогноза

Ценова цел

By TipRanks

108.33% нагоре

12-месечна прогноза

Среден 0.75 USD 108.33%

Висок 0.75 USD

Нисък 0.75 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за CytoSorbents Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на CytoSorbents Corp през последните 3 месеца.

Настроение

By Acuity

135 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.